Global Hospital-Acquired Pneumonia Drugs (Phase III) Market USD 3.8 Billion by 2020, Research Study by iHealthcareAnalyst, Inc.
Maryland Heights, MO, December 01, 2016 --(PR.com)-- The global hospital-acquired pneumonia drugs (Phase III) market is estimated to reach USD 3.8 Billion in 2020, published by iHealthcareAnalyst, Inc.
Visit the Hospital-Acquired Pneumonia Drugs (Phase III) Market – Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate 2016-2020 report at https://www.ihealthcareanalyst.com/report/hospital-acquired-pneumonia-drugs-market/
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is caused due to the most common pathogens such as gram-negative bacilli and Staphylococcus aureus; whereas, antibiotic-resistant organisms are an important concern. There are two subtypes of HAP: Ventilator-associated pneumonia (VAP) and Healthcare-associated pneumonia (HCAP). Hospital-acquired pneumonia also called healthcare associated pneumonia, nosocomial or ventilator associated pneumonia is caused due to infections acquired in hospital premise. The disease is different from community acquired pneumonia in that the former is mainly caused due to multi drug resistant microorganisms. Majority of these infections are caused by microorganism’s resistance to conventional drugs. These include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Besides prompt antibiotic treatment, supportive measure for organ failure (such as cardiac decompensation) are also important.
The global hospital-acquired pneumonia drugs (Phase III) market report estimates the market size (Revenue USD million – 2013 to 2020) for key market segments based on the clinical pipeline analysis of phase 1, 2 and 3 drugs such as Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate, and forecasts growth trends (CAGR% – 2016 to 2020).
The global hospital-acquired pneumonia drugs (Phase III) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital-acquired pneumonia drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global hospital-acquired pneumonia drugs (Phase III) market and included in this report are Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Inc., Sanofi SA, and Valneva SE.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hospital-acquired-pneumonia-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Visit the Hospital-Acquired Pneumonia Drugs (Phase III) Market – Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate 2016-2020 report at https://www.ihealthcareanalyst.com/report/hospital-acquired-pneumonia-drugs-market/
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is caused due to the most common pathogens such as gram-negative bacilli and Staphylococcus aureus; whereas, antibiotic-resistant organisms are an important concern. There are two subtypes of HAP: Ventilator-associated pneumonia (VAP) and Healthcare-associated pneumonia (HCAP). Hospital-acquired pneumonia also called healthcare associated pneumonia, nosocomial or ventilator associated pneumonia is caused due to infections acquired in hospital premise. The disease is different from community acquired pneumonia in that the former is mainly caused due to multi drug resistant microorganisms. Majority of these infections are caused by microorganism’s resistance to conventional drugs. These include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Besides prompt antibiotic treatment, supportive measure for organ failure (such as cardiac decompensation) are also important.
The global hospital-acquired pneumonia drugs (Phase III) market report estimates the market size (Revenue USD million – 2013 to 2020) for key market segments based on the clinical pipeline analysis of phase 1, 2 and 3 drugs such as Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate, and forecasts growth trends (CAGR% – 2016 to 2020).
The global hospital-acquired pneumonia drugs (Phase III) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital-acquired pneumonia drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global hospital-acquired pneumonia drugs (Phase III) market and included in this report are Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Inc., Sanofi SA, and Valneva SE.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hospital-acquired-pneumonia-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 736-9294
https://www.ihealthcareanalyst.com/
Contact
Categories